Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Curium strikes up to $8B deal for radiopharma rival Lantheus
Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion. | Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion.
TL;DRAI
Curium acquires Lantheus for up to $8B ($102.50/share + CVR), closing Q1 2027. Merges Curium's production network (80+ sites) with Lantheus' franchises (Pylarify, Definity, Neuraceq) across 70+ countries—consolidating radiopharmaceutical supply chain.
601 words~3 min read
